Vascular Endothelial Growth Factor
Studies from C.C. Lin and co-authors have provided new information about vascular endothelial growth factor
Published in Cancer Weekly, June 2nd, 2009
"To maximally inhibit EGFR and then downstream VEGF activity, this phase I study was initiated to determine the maximum tolerated dose (MTD) of erlotinib with Wxed-dose cetuximab, and then combine with bevacizumab in patients with advanced malignancies. Patients and methods Patients with advanced malignancies likely to express EGFR were treated with a full dose of cetuximab intravenous weekly,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-06-02)
More Articles from Cancer Weekly
- Allergies
Study data from National Institute of Allergy and Infectious Diseases update knowledge of allergies - Allos Therapeutics, Inc.
Allos Therapeutics Announces Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate to be Presented at ASCO 2009 - Cancer Gene Therapy
New cancer gene therapy findings from University of Saskatchewan described - Cancer Gene Therapy
Reports outline cancer gene therapy study findings from University of Navarra - Cancer Gene Therapy
Research from Central South University has provided new information about cancer gene therapy - Cancer Gene Therapy
Research reports from University Hospital provide new insights into cancer gene therapy - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
